​​FDA to al­low 23andMe to re­port more BR­CA vari­ants; Janssen se­cures deal with AI-drug dis­cov­ery out­fit

23andMe re­ceived FDA clear­ance to re­port an ad­di­tion­al 41 vari­ants in the BR­CA1 and BR­CA2 genes, which are as­so­ci­at­ed with a high­er risk of breast, ovar­i­an, prostate and pan­cre­at­ic can­cer.

Many of the ad­di­tion­al vari­ants are more like­ly to oc­cur in Black and His­pan­ic pop­u­la­tions. It’s the fourth FDA clear­ance for the gener­ic test­ing com­pa­ny. — An­na Brown 

Janssen part­ners with AI-fo­cused drug dis­cov­ery com­pa­ny 

AI drug dis­cov­ery out­fit In­tel­li­gent OMICS part­nered with John­son & John­son’s  Janssen to find a treat­ment for hema­to­log­i­cal can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER